Abbonarsi

Polyp characteristics at screening colonoscopy and post-colonoscopy colorectal cancer mortality: a retrospective cohort study - 17/05/23

Doi : 10.1016/j.gie.2023.01.021 
Jasmin Zessner-Spitzenberg, MD 1, 2, Lena Jiricka, BSc 3, Elisabeth Waldmann, MD, PhD 1, 2, Lisa-Maria Rockenbauer, BSc 1, 2, Jeremy Cook, BSc 1, 2, Anna Hinterberger, MD 1, 2, Barbara Majcher, MD 1, 2, Aleksandra Szymanska, BSc 2, Arno Asaturi 2, Michael Trauner, MD 1, Monika Ferlitsch, MD 1, 2,
1 Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria 
3 Center for Medical Statistics, Informatics and Intelligent Systems, Institute of Clinical Biometrics, Medical University of Vienna, Vienna, Austria 
2 Quality Assurance Working Group, Austrian Society of Gastroenterology and Hepatology, Vienna, Austria 

Reprint requests: Monika Ferlitsch, MD, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria, Waehringer Guertel 18-20, 7i, 1090 Vienna, Austria. Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical University of Vienna Austria, Waehringer Guertel 18-20, 7i Vienna 1090 Austria

Abstract

Background and Aims

Polyp size and high-grade dysplasia in polyps at screening colonoscopy are considered risk factors for post-colonoscopy colorectal cancer (PCCRC) development and death, which might be averted by surveillance colonoscopy. However, robust evidence backing these risk factors is lacking. We aimed to investigate whether polyp size or dysplasia grade is associated with PCCRC mortality.

Methods

This was a retrospective study including individuals of the Austrian Quality Certificate for Screening Colonoscopy who underwent a colonoscopy between January 2007 and December 2020. We investigated the association of polyp size and dysplasia in polyps with PCCRC mortality according to Cox regression analysis. In addition, whether patients with certain polyp characteristics had similar risk for CRC death compared with the Austrian population was assessed by calculating standardized mortality ratios (SMRs).

Results

A total of 316,001 individuals were included. After a median follow-up time of 5.27 years (95% confidence interval [CI], 5.25-5.29), a significant association of polyps 10 to 20 mm (hazard ratio, 4.00; 95% CI, 2.46-6.50; P   < .001) as well as high-grade dysplasia (hazard ratio, 6.61; 95% CI, 3.31-13.2; P   < .001) with PCCRC death was observed. PCCRC mortality was significantly lower than the expected CRC mortality in the general population in patients with polyps  < 10 mm and without high-grade dysplasia (SMR, .27; 95% CI, .21-.33; P   < .001), which was not observed for patients with polyps ≥10 mm or with high-grade dysplasia (SMR, 2.05; 95% CI, 1.64-2.57; P   < .001).

Conclusions

Polyp size ≥10 mm and high-grade dysplasia are associated with PCCRC mortality in screening patients. The data suggest that these patients might benefit most from surveillance colonoscopy.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : CI, CRC, HGD, HR, ICD-10, PCCRC, SMR, SSL, WHO


Mappa


  DISCLOSURE: Dr Trauner: Advisor for Abbvie, Albireo, BiomX, BI, Falk, Gilead, Genfit, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens, and Shire. Grants from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and Ultragenyx. Travel grants from Abbvie, Falk Foundation, Gilead, Intercept, and Janssen. Speakers bureau for BMS, Falk Foundation, Gilead, Intercept, MSD, and Roche. Property rights from The Medical Universities of Graz and Vienna, which have filed patents on medical use of norUDCA (co-inventor). All other authors disclosed no financial relationships.The Main Association of Statutory Insurance Institutions, the Austrian Society for Gastroenterology and Hepatology, and the Austrian Cancer Aid are supporting the Austrian quality certificate for screening colonoscopy (Qualitätszertifikat Darmkrebsvorsorge ).
 DIVERSITY, EQUITY, AND INCLUSION: We worked to ensure gender balance in the recruitment of human subjects. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.


© 2023  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 97 - N° 6

P. 1109 - giugno 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Cold snare EMR for the removal of large duodenal adenomas
  • Hunter Wang, Mayenaaz Sidhu, Sunil Gupta, Oliver Cronin, Timothy O’Sullivan, Anthony Whitfield, Nicholas G. Burgess, Michael J. Bourke
| Articolo seguente Articolo seguente
  • Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study
  • Yoshiki Kajiwara, Shiro Oka, Shinji Tanaka, Takahiro Nakamura, Shoichi Saito, Yosuke Fukunaga, Manabu Takamatsu, Hiroshi Kawachi, Kinichi Hotta, Hiroaki Ikematsu, Motohiro Kojima, Yutaka Saito, Masayoshi Yamada, Yukihide Kanemitsu, Shigeki Sekine, Shinji Nagata, Kazutaka Yamada, Nozomu Kobayashi, Soichiro Ishihara, Yusuke Saitoh, Kenji Matsuda, Kazutomo Togashi, Koji Komori, Megumi Ishiguro, Toshio Kuwai, Takashi Okuyama, Akihiro Ohuchi, Shinobu Ohnuma, Kazuhiro Sakamoto, Tamotsu Sugai, Kenji Katsumata, Hiro-o Matsushita, Hiro-o Yamano, Hirotsugu Eda, Toshio Uraoka, Naohiko Akimoto, Hirotoshi Kobayashi, Yoichi Ajioka, Kenichi Sugihara, Hideki Ueno

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.